Abbott (NYSE:ABT) said today it launched its Proclaim dorsal root ganglion neurostimulator system designed to treat pain in patients with complex regional pain syndrome of the lower limbs.
The company’s Proclaim DRG system is designed to be used via Bluetooth with an Apple (NSDQ:AAPL) iPod touch as a system controller and is magnetic resonance-conditional and recharge free, all upgrades from previous versions of the device, the Abbott Park, Ill.-based company said.
Abbott said it originally launched the DRG therapy system in 2016 and data from the Accurate study of it showed the system delivers “superior pain relieve in patients with CRPS compared to traditional spinal cord stimulation therapy,” according to a press release.
Results from the study also indicated that patients receiving DRG stimulation reported better therapeutic targeting and a reduction in paresthesia compared to SCS.
“Both clinical and real world data have shown that DRG stimulation produces long-term, meaningful pain relief for patients with complex regional pain syndromes – like those resulting after total knee arthroplasty, foot surgery or hernia surgery. The ability to offer DRG stimulation on the Proclaim platform is a very exciting advancement for those of us who treat patients with these debilitating conditions and want to provide relief from hard-to-treat neuropathic conditions,” Accurate study co-principal investigator Dr. Timothy Deer of Charleston, Va.’s Spine and Nerve Center said in a prepared statement.
Last week, Abbott released data from the Broaden study of its deep brain stimulation technology used to treat chronic, treatment-resistant depression, touting a nearly 50% response to the treatment.
See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.